Program in Translational Lung Research, Division of Pulmonary Sciences and Critical Care Medicine, Univ. of Colorado Denver, Anschutz Medical Campus, Research 2 - 9th floor, Rm. 9001; Mail stop C-272, 12700 East 19th Ave., Aurora, CO 80045.
Am J Physiol Lung Cell Mol Physiol. 2013 Nov 15;305(10):L725-36. doi: 10.1152/ajplung.00186.2013. Epub 2013 Sep 13.
Despite the importance of pulmonary veins in normal lung physiology and the pathobiology of pulmonary hypertension with left heart disease (PH-LHD), pulmonary veins remain largely understudied. Difficult to identify histologically, lung venous endothelium or smooth muscle cells display no unique characteristic functional and structural markers that distinguish them from pulmonary arteries. To address these challenges, we undertook a search for unique molecular markers in pulmonary veins. In addition, we addressed the expression pattern of a candidate molecular marker and analyzed the structural pattern of vascular remodeling of pulmonary veins in a rodent model of PH-LHD and in lung tissue of patients with PH-LHD obtained at time of placement on a left ventricular assist device. We detected urokinase plasminogen activator receptor (uPAR) expression preferentially in normal pulmonary veins of mice, rats, and human lungs. Expression of uPAR remained elevated in pulmonary veins of rats with PH-LHD; however, we also detected induction of uPAR expression in remodeled pulmonary arteries. These findings were validated in lungs of patients with PH-LHD. In selected patients with sequential lung biopsy at the time of removal of the left ventricular assist device, we present early data suggesting improvement in pulmonary hemodynamics and venous remodeling, indicating potential regression of venous remodeling in response to assist device treatment. Our data indicate that remodeling of pulmonary veins is an integral part of PH-LHD and that pulmonary veins share some key features present in remodeled yet not normotensive pulmonary arteries.
尽管肺静脉在正常肺生理学和左心疾病相关肺动脉高压(PH-LHD)的病理生理学中具有重要意义,但肺静脉仍然在很大程度上未得到充分研究。肺静脉在组织学上难以识别,肺静脉内皮细胞或平滑肌细胞没有独特的特征性功能和结构标志物将其与肺动脉区分开来。为了解决这些挑战,我们寻找了肺静脉中的独特分子标志物。此外,我们分析了候选分子标志物的表达模式,并分析了 PH-LHD 啮齿动物模型和左心室辅助装置置入时获得的 PH-LHD 患者肺组织中肺静脉的血管重构结构模式。我们在小鼠、大鼠和人肺的正常肺静脉中优先检测到尿激酶型纤溶酶原激活物受体 (uPAR) 的表达。PH-LHD 大鼠的肺静脉中 uPAR 的表达仍然升高;然而,我们还检测到重塑的肺动脉中 uPAR 表达的诱导。这些发现在 PH-LHD 患者的肺中得到了验证。在左心室辅助装置取出时进行连续肺活检的选定患者中,我们提供了早期数据,表明肺血流动力学和静脉重构得到改善,表明静脉重构对辅助装置治疗有潜在的逆转。我们的数据表明,肺静脉重构是 PH-LHD 的一个组成部分,肺静脉与重塑但非正常血压的肺动脉具有一些共同的关键特征。